AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11700394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of rhAPC (12, 18, 24, or 30 microg/kg/hr) for 48 or 96 hrs
Number of subjects: 131
Study 11700394 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 48 or 96 hrs
Number of subjects: 131
Study 9210983 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee with milk
Number of subjects: 12
Study 9210983 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea with milk
Number of subjects: 12
Study 9210983 — intervention group
Group type: COMPARATOR
Intervention: Control (black coffee or black tea without milk)
Number of subjects: 12
Study 7961049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangential dipole activity
Number of subjects: 40
Study 7961049 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial dipole activity
Number of subjects: 40
Study 7961049 — intervention group
Group type: EXPERIMENTAL
Intervention: Retesting after three weeks
Number of subjects: 40
Study 7961049 — intervention group
Group type: EXPERIMENTAL
Intervention: Age correlation
Number of subjects: 40
Study 3300294 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mL of 100% alcohol
Number of subjects: 8
Study 3300294 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy alcohol intake
Number of subjects: 8
Study 3300294 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute moderate alcohol intake
Number of subjects: 8
Study 29366377 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-pulse NMES
Number of subjects: 27
Study 26409172 — intervention group
Group type: EXPERIMENTAL
Intervention: CIM331
Number of subjects: 0
Study 26409172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24750301 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 32
Study 24750301 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32
Study 22901887 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg three times a week for 6 months
Number of subjects: 141
Study 22901887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 22901887 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 141
Study 20739893 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced laryngeal mask airway (RLMA)
Number of subjects: 134
Study 20739893 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 134
Study 17394477 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized face-to-face counseling session followed by phone contacts every 3 months.
Number of subjects: 632
Study 17394477 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 632
Study 15680528 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic cohort
Number of subjects: 61
Study 15680528 — intervention group
Group type: COMPARATOR
Intervention: Normothermic cohort
Number of subjects: 61
Study 12093059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 286
Study 12093059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 9840513 — intervention group
Group type: COMPARATOR
Intervention: Cold laryngeal mirror stimulation
Number of subjects: 14
Study 9840513 — intervention group
Group type: COMPARATOR
Intervention: Cold water swallowing
Number of subjects: 14
Study 8023546 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (Havrix) stored at 37 degrees C for 1 week
Number of subjects: 2
Study 8023546 — intervention group
Group type: COMPARATOR
Intervention: Inactivated hepatitis A vaccine (Havrix) stored at 2-8 degrees C
Number of subjects: 2
Study 2657055 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg once daily
Number of subjects: 165
Study 2657055 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily
Number of subjects: 165
Study 31928364 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum micronutrient formula
Number of subjects: 78
Study 31928364 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6 (80 mg/day)
Number of subjects: 78
Study 30515840 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction from provoking cues
Number of subjects: 119
Study 30515840 — intervention group
Group type: COMPARATOR
Intervention: No-distraction control condition
Number of subjects: 119
Study 30057745 — intervention group
Group type: EXPERIMENTAL
Intervention: GM604
Number of subjects: 12
Study 30057745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30057745 — intervention group
Group type: EXPERIMENTAL
Intervention: GM604 (compassionate treatment)
Number of subjects: 12
Study 26531865 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal SCIT (30,000 standardized quality units) plus anti-IL-4 (VAK694)
Number of subjects: 37
Study 26531865 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal SCIT (30,000 standardized quality units) plus placebo antibody
Number of subjects: 37
Study 26531865 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (placebo SCIT and placebo antibody)
Number of subjects: 37
Study 24978623 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet parenting education and support intervention
Number of subjects: 60
Study 24978623 — intervention group
Group type: COMPARATOR
Intervention: Online education healthy lifestyle course
Number of subjects: 60
Study 23022391 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Ze 440
Number of subjects: 162
Study 23022391 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Ze 440
Number of subjects: 162
Study 23022391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 23022391 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg Ze 440
Number of subjects: 162
Study 19933962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (physician and pharmacist collaboration)
Number of subjects: 402
Study 19933962 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 402
Study 17514629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse methylprednisolone (MP)
Number of subjects: 19
Study 17514629 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (P)
Number of subjects: 19
Study 15302290 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal surgical treatment plus adhesion barrier (SprayGel)
Number of subjects: 66
Study 15302290 — intervention group
Group type: COMPARATOR
Intervention: Optimal surgical treatment alone
Number of subjects: 66
Study 11251012 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg (20 mg maximum)
Number of subjects: 32
Study 11251012 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 32
Study 11251012 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 32
Study 10203559 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition via nasogastric tube
Number of subjects: 32
Study 10203559 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 32
Study 10203559 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 32
Study 8580980 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxisylyte 10 mg
Number of subjects: 30
Study 8580980 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxisylyte 20 mg
Number of subjects: 30
Study 8580980 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxisylyte 30 mg
Number of subjects: 30
Study 8580980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2090770 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon alpha‐2b (rIFN alpha‐2b) 5 MU/m2 thrice weekly for 16 weeks
Number of subjects: 40
Study 2090770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 772817 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (50 to 175 mg/day)
Number of subjects: 16
Study 772817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 772817 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (after placebo)
Number of subjects: 16
Study 772817 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 16
Study 31166260 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 74
Study 31166260 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 74
Study 31166260 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Number of subjects: 74
Study 28459181 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 40
Study 28459181 — intervention group
Group type: COMPARATOR
Intervention: Advanced Moist Wound Therapy (Control)
Number of subjects: 40
Study 26683057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose-induction oral immunotherapy (OIT) with 3 ml of milk, administered daily after a 5-day hospital build-up period.
Number of subjects: 37
Study 26683057 — intervention group
Group type: COMPARATOR
Intervention: Control group (complete elimination of milk intake).
Number of subjects: 37
Study 23660209 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 28
Study 23660209 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral fusion (PLF)
Number of subjects: 28
Study 23660209 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TLIF
Number of subjects: 28
Study 23660209 — intervention group
Group type: COMPARATOR
Intervention: PLF
Number of subjects: 28
Study 21834711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with 50 μm aluminum oxide particles at a pressure of 87 psi
Number of subjects: 33
Study 21834711 — intervention group
Group type: COMPARATOR
Intervention: Control (excavator)
Number of subjects: 33
Study 21834711 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate
Number of subjects: 33
Study 21834711 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% polyacrylic acid
Number of subjects: 33
Study 21834711 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of flour pumice and water
Number of subjects: 33
Study 19192230 — intervention group
Group type: EXPERIMENTAL
Intervention: ELTGOL plus medical therapy
Number of subjects: 59
Study 19192230 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 59
Study 17364305 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity, high‐frequency TENS (HI TENS)
Number of subjects: 21
Study 17364305 — intervention group
Group type: COMPARATOR
Intervention: Low intensity, high‐frequency TENS (LI TENS)
Number of subjects: 21
Study 15488162 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing of the CVP using normal saline solution before each closure and every 6 hours
Number of subjects: 83
Study 15488162 — intervention group
Group type: COMPARATOR
Intervention: Closure of the CVP using an obturator after the suspension of the infused therapy
Number of subjects: 83
Study 11201509 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (Premarin 0.625 mg) and oral micronized progesterone (Prometrium 200 mg)
Number of subjects: 21
Study 11201509 — intervention group
Group type: COMPARATOR
Intervention: Estrogen (Premarin 0.625 mg) and medroxyprogesterone acetate (Provera 5 mg)
Number of subjects: 21
Study 9571553 — intervention group
Group type: EXPERIMENTAL
Intervention: Final smoothing after PRK or LASIK
Number of subjects: 147
Study 9571553 — intervention group
Group type: COMPARATOR
Intervention: Patched immediately after PRK or LASIK
Number of subjects: 147
Study 1637279 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone metasulphobenzoate for 3 months
Number of subjects: 113
Study 1637279 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 113
Study 6711431 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 17
Study 6711431 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 17
Study 6711431 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 17
Study 6711431 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study 30457557 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan
Number of subjects: 50
Study 30457557 — intervention group
Group type: COMPARATOR
Intervention: Surgicel
Number of subjects: 50
Study 29582360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu® AuraGain™
Number of subjects: 165
Study 29582360 — intervention group
Group type: COMPARATOR
Intervention: LMA® Supreme™
Number of subjects: 165
Study 27210823 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 50
Study 27210823 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 50
Study 23827130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine ingestion (400 mg/d) for 4 weeks
Number of subjects: 22
Study 23827130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21073640 — intervention group
Group type: EXPERIMENTAL
Intervention: Make A Difference about Art programme (art therapy intervention)
Number of subjects: 297
Study 19183113 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced monitoring (AM) group
Number of subjects: 40
Study 19183113 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring (CM) group
Number of subjects: 40
Study 17510712 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE (Ivoclar Vivadent)
Number of subjects: 10
Study 17510712 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus-Self-Etch (Kerr)
Number of subjects: 10
Study 17510712 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian SPE (Bisco)
Number of subjects: 10
Study 17510712 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt Self-Etch (3M Espe)
Number of subjects: 10
Study 17510712 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Up Bond F (Tokuyama)
Number of subjects: 10
Study 15085873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine solution applied into the inner space of 23 fixtures (test group)
Number of subjects: 12
Study 15085873 — intervention group
Group type: COMPARATOR
Intervention: Saline applied into the inner space of 23 fixtures (control group)
Number of subjects: 12
Study 11905780 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy for advanced laryngeal cancer
Number of subjects: 0
Study 11905780 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy given concomitantly with radiotherapy
Number of subjects: 0
Study 9737644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.025-0.4 mg/day
Number of subjects: 0
Study 9737644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (higher doses)
Number of subjects: 0
Study 9737644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (long-term administration)
Number of subjects: 0
Study 9737644 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin
Number of subjects: 0
Study 7536025 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy consisting of carboplatin 1600 mg m-2, thiotepa 480 mg m-2 and cyclophosphamide 6 g m-2 (CTC) followed by PBSC transplantation
Number of subjects: 29
Study 7536025 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (Filgrastim) 300 microgram s.c. daily
Number of subjects: 29
Study 2665058 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (7.5 U fast-acting insulin/kg b.w. as a bolus followed by continuous infusion of 15 U/kg b.w. for 1 hour)
Number of subjects: 21
Study 2665058 — intervention group
Group type: COMPARATOR
Intervention: Control (no insulin treatment)
Number of subjects: 21
Study 2665058 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 21
Study 2665058 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study 903408 — intervention group
Group type: EXPERIMENTAL
Intervention: Monterey program for the syntactic structure 'is interrogative' plus an extended transfer program
Number of subjects: 9
Study 903408 — intervention group
Group type: EXPERIMENTAL
Intervention: Monterey 'is interrogative' program alone
Number of subjects: 9
Study 903408 — intervention group
Group type: COMPARATOR
Intervention: Control activity (articulation training)
Number of subjects: 9
Study 31076561 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin combined with neoadjuvant chemotherapy and trastuzumab
Number of subjects: 0
Study 31076561 — intervention group
Group type: COMPARATOR
Intervention: Control regimen without metformin
Number of subjects: 0
Study 31076561 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin-containing arm
Number of subjects: 0
Study 28613947 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise (CON)
Number of subjects: 12
Study 28613947 — intervention group
Group type: COMPARATOR
Intervention: Circuit-based exercise (CIRC)
Number of subjects: 12
Study 24299007 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG membrane
Number of subjects: 37
Study 24299007 — intervention group
Group type: COMPARATOR
Intervention: Collagen membrane (control)
Number of subjects: 37
Study 23324914 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0
Study 23324914 — intervention group
Group type: COMPARATOR
Intervention: Surgical valve replacement
Number of subjects: 0
Study 21981870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand acupuncture
Number of subjects: 20
Study 21981870 — intervention group
Group type: COMPARATOR
Intervention: Laser-needle acupuncture
Number of subjects: 20
Study 19524144 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartslag Limburg intervention
Number of subjects: 3114
Study 19524144 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3114
Study 17047539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (15 mug)
Number of subjects: 60
Study 17047539 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 60
Study 12774010 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE (epirubicin, cyclophosphamide, and etoposide)
Number of subjects: 50
Study 12774010 — intervention group
Group type: COMPARATOR
Intervention: PACE (prednisolone + ACE)
Number of subjects: 50
Study 10669686 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (2 x 100 microg qid for 6 weeks)
Number of subjects: 19
Study 10669686 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to salbutamol, 2 x 100 microg qid for 6 weeks)
Number of subjects: 19
Study 10669686 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 19
Study 10669686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9209926 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyzer with spacing filaments (PAN 650 SF Asahi)
Number of subjects: 0
Study 9209926 — intervention group
Group type: COMPARATOR
Intervention: Standard dialyzer without spacing filaments
Number of subjects: 0
Study 8092771 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxon
Number of subjects: 102
Study 8092771 — intervention group
Group type: COMPARATOR
Intervention: Dexon Plus
Number of subjects: 102
Study 3125004 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide enteral formula
Number of subjects: 12
Study 3125004 — intervention group
Group type: COMPARATOR
Intervention: Standard isotonic enteral formula
Number of subjects: 12
Study 30700257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (N=5) received repeated safety climate (SC) measurement and feedback, and patient record reviews using a specialized trigger tool.
Number of subjects: 11
Study 30700257 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=6) received baseline and end SC measurement only.
Number of subjects: 11
Study 30700257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (N=5) applied the trigger tool to patient records.
Number of subjects: 11
Study 30700257 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-study questionnaire for intervention group (N=5).
Number of subjects: 11
Study 30700257 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews (N=9) with intervention group staff.
Number of subjects: 11
Study 27986296 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed media education intervention (3 biweekly sessions with lectures, videos, role-play, and feedback)
Number of subjects: 84
Study 27986296 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed media education intervention
Number of subjects: 84
Study 27986296 — intervention group
Group type: COMPARATOR
Intervention: Self-directed readings (control group)
Number of subjects: 84
Study 26317782 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) at doses of 6 mg/m2/d, 10 mg/m2/d, and 14 mg/m2/d administered thrice daily.
Number of subjects: 27
Study 26317782 — intervention group
Group type: EXPERIMENTAL
Intervention: Single point plasma cortisol measurements.
Number of subjects: 27
Study 26317782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol concentrations at 1000h and 1400h.
Number of subjects: 27
Study 26317782 — intervention group
Group type: EXPERIMENTAL
Intervention: 0800-1200h ΔACTH measurements.
Number of subjects: 27
Study 22672584 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately placed implants in sockets with periapical pathology
Number of subjects: 27
Study 22672584 — intervention group
Group type: COMPARATOR
Intervention: Immediately placed implants in sockets without periapical pathology (control group)
Number of subjects: 27
Study 22672584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 27
Study 21288341 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0
Study 21288341 — intervention group
Group type: COMPARATOR
Intervention: Depression awareness training
Number of subjects: 0
Study 19692147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Number of subjects: 336
Study 19692147 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen with codeine 1 mg/kg/dose
Number of subjects: 336